AKT1 and non-small cell lung carcinoma: In particular, many studies have confirmed that, in NSCLC, the abnormal activation of the PI3K/AKT and Ras/ERK signaling pathways plays a critical role in promoting the proliferation and invasion of lung cancer cells, as well as resistance to chemoradiotherapy and targeted therapy [10, 11].